COVID-19 did not significantly alter MG course in most patients, but certain factors predicted poor outcomes, including generalized MG, CKD, and malignancies. Immunosuppressive therapy reduced risks ...

Comorbidities and older age increase the risk of severe COVID-19 in MG patients, but not susceptibility to infection. MG treatments, including corticosteroids and immunosuppressants, do not heighten ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the University ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...